From the Journals
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
CHICAGO – Patients who received SC-PEG had similar serum asparaginase activity, toxicities, and survival as patients...
Data link breast implant–associated anaplastic large cell lymphoma to textured devices, but the FDA allowed continued U.S. sales.
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
SILVER SPRING, MD. – Women report personal horror stories of apparent breast-implant complications, but systematically-collected data remain...
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
The advisory panel seemed the current implant screening recommendation using MRI “useless.” They urged the adoption of ultrasound as a more...